Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients Stable (no update expected for reasons given in 'What's new')
This is an updated version of the original Cochrane review published in Issue 3, 2006. Selenium supplements are frequently used by cancer patients. Selenium is an essential trace element and is involved in antioxidant protection and the redox‐regulation in humans. Several adverse effects of radiotherapy and chemotherapy in cancer patients as well as cellular processes that maintain chronic lymphoedema have been linked to oxidative cell processes in the human body. Selenium has been claimed to alleviate side effects of conventional cancer therapy and recently been investigated as a remedy against chemotherapy and radiotherapy‐associated side effects and secondary lymphoedema.
This review assessed the effects of supplementary selenium on adverse effects of conventional radiotherapy, chemotherapy, or surgery in oncology patients and on quality of life/performance status during and after oncological treatment.
The Cochrane Pain, Palliative & Supportive Care Trials Register, the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects (DARE), CENTRAL, MEDLINE, EMBASE, SIGLE, Cancerlit, CCMed, the German online register for cancer trials, the ISRCTN, the mRCT, the NCI Clinical Trials register databases were searched and most updated in July 2007.
Randomised controlled trials (RCTs) of selenium mono‐supplements in cancer patients undergoing tumour specific therapy, such as chemotherapy, radiotherapy or surgery.
Data collection and analysis
Two review authors independently checked trials for eligibility, extracted data and assessed trial quality.
One new included study as well as further participants to a study already included was added to this update involving a further 39 participants. There were a total of three studies included involving 162 participants for this update.
For this review two RCTs were included investigating secondary lymphoedema in 60 women after breast cancer surgery and 20 men and women after head and neck cancer surgery. One ongoing trial with preliminary results of 82 participants was also identified studying radiotherapy induced diarrhoea as a secondary outcome. All studies had considerable drawbacks with regards to quality and reporting.
One study on secondary lymphoedema reported a decreased number of recurrent erysipela infections in the selenium supplementation group compared to placebo. The second study reported a decreased facial swelling in the selenium group in a two‐week period following surgical tumour resection. However, results must be interpreted with caution and cannot be generalised to other populations.
The ongoing trial on radiotherapy associated diarrhoea preliminarily reported a lower incidence of diarrhoea in participants receiving selenium supplementation concomitant to pelvic radiation, however, no data were presented. We must await publication of final results to discuss these findings in detail.
No RCTs were found studying the effect of selenium supplementation on other therapy‐associated toxicities or quality of life/performance status in cancer patients.
There is insufficient evidence at present that selenium supplementation alleviates the side effects of tumour specific chemotherapy or radiotherapy treatments or that it improves the after‐effects of surgery, or improves quality‐of‐life in cancer patients or reduces secondary lymphoedema. To date, research findings do not provide a basis for any recommendation in favour or against selenium supplementation in cancer patients. Potential hazards of supplementing a trace mineral should be kept in mind. Since the last version of this review, the one new additional study has not provided information to change the conclusions of the original review.
Gabriele Dennert, Markus Horneber
Plain language summary
Selenium supplements for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients
There is no evidence that selenium supplements reduce side effects of chemotherapy, radiotherapy or the effects of surgery in cancer patients. Selenium is a mineral necessary for human health. Selenium acts against cell damage in the body and might help to alleviate the side effects of therapies in cancer patients, such as nausea, diarrhoea or the lymph retention in limbs. Selenium supplements are frequently used by cancer patients. This systematic review looked at studies providing selenium supplements to cancer patients and found no clear evidence that selenium supplements improve side effects of cancer therapy. No adverse effects were reported in the studies, but evidence of overdosing, all be it unintentional and selenium intoxication has occurred in several selenium users. More research is needed to find out which doses of selenium supplements can be reasonably used by cancer patients and whether selenium supplements can affect the side effects of cancer therapy.
Gabriele Dennert, Markus Horneber
Implications for practice
The currently available evidence is insufficient to assess reliably the possible role of selenium supplementation on toxicities related to oncology treatments, on the development and severity of secondary lymphoedema and on quality of life during antineoplastic treatments. The quality of the studies prohibits us from extrapolating any effects observed to the general population level. Currently, research findings do not provide a basis for any recommendation in favour or against selenium supplementation in cancer patients. Nevertheless, the potential hazards of supplementing a trace mineral should always be kept in mind.
Since the last version of this review the additional participants have not provided additional information to change the conclusions.
Implications for research
As it is likely that a considerable number of cancer patients will seek "complementary" treatments to alleviate adverse effects connected with conventional therapy, further research is desirable.
Supplementation with sodium selenite is currently under investigation in RCTs and robust and sound replication of the existing trial might be useful. However, no systematic dosage‐finding study has been reported so far. An adequate dosage‐finding study seems as desirable as adequate reporting of completed, ongoing and future trials.Get full text at The Cochrane Library
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.